More Americans suffer a traumatic brain injury (TBI) each year (3.5 million) than those diagnosed with breast cancer, HIV and multiple sclerosis combined (1.6 million), according to the latest estimates from the U.S. Centers for Disease Control and Prevention. Researchers have worked diligently for decades to develop a successful acute treatment for this devastating, life-altering condition. But after scores of failed clinical trials, we still don't have an FDA-approved treatment for TBI.
Failure to find a treatment can be partly explained by the complexity of the condition. Beyond potentially deadly damage to the brain, TBI can cause severe problems for organs throughout the body.
Researchers are now studying a treatment that may address TBI through multiple pathways - progesterone. Although widely known as a pregnancy hormone, clinical studies have shown progesterone is made in both male and female central nervous systems and offers neurological protection.
SyNAPSe(R), a global, Phase III clinical trial, is studying the safety and efficacy of progesterone as a potential treatment for severe TBI. If the study is successful, the treatment could become the world's first approved TBI treatment. Learn more about the promise of progesterone and the SyNAPSe trial at www.synapse-trial.com.